7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial
Titel:
7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial
Auteur:
Zhou, C. Xiong, A. Zhao, J. Li, W. Bi, M. Chen, J. Li, K. Miao, L. Mao, Y. Wang, D. Liu, C. Zeng, A. Li, R. Pan, Y. Hu, Y. Zhang, X. Niu, H. Du, Y. Sun, Y. Liu, Z.